Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 52Fallopian Tube Neoplasms 48Endometrial Neoplasms 17Uterine Cervical Neoplasms 16Carcinoma, Ovarian Epithelial 15Brenner Tumor 15Carcinoma, Non-Small-Cell Lung 7Breast Neoplasms 7Esophageal Neoplasms 6Pancreatic Neoplasms 5Neoplasm Metastasis 5Endometrial Adenocarcinoma 5Stomach Neoplasms 4Melanoma 4Lung Neoplasms 4Triple Negative Breast Neoplasms 3Testicular Neoplasms 3Prostatic Neoplasms 3Peritoneal Neoplasms 3Neoplasms 3Carcinoma, Renal Cell 3Uterine Neoplasms 2Urinary Bladder Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Sarcoma 2Salivary Gland Neoplasms 2Recurrence 2Platinum-Refractory Fallopian Tube Carcinoma 2Ovarian Germ Cell Cancer 2

Interventions

enzalutamide 1Taxes 1Paclitaxel 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrent Endometrial Endometrioid Adenocarcinoma × Taxes × Gynecologic × Clear all
NCT02684227 2025-03-19

Enzalutamide, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrioid Endometrial Cancer

M.D. Anderson Cancer Center

Phase 2 Completed
50 enrolled 14 charts
Gynecologic

Recurrent Endometrial Endometrioid Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡